80% Of Cerezyme Patients Have Returned Since Shipments Resumed, Genzyme Says
This article was originally published in The Pink Sheet Daily
Executive Summary
At J.P. Morgan conference, CEO Termeer says manufacturing problems are in the past and priorities include building redundant capacity to avoid any future shortages.